Sahar Javanmard

Array ( [id] => 18404501 [patent_doc_number] => 20230165852 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-01 [patent_title] => METHOD FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS USING DOPAMINE D3 PARTIAL AGONISTS [patent_app_type] => utility [patent_app_number] => 17/922767 [patent_app_country] => US [patent_app_date] => 2021-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5792 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17922767 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17034969 [patent_doc_number] => 20210251927 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/245497 [patent_app_country] => US [patent_app_date] => 2021-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25189 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 174 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17245497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18699978 [patent_doc_number] => 11786464 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-17 [patent_title] => PH responsive block copolymer compositions and micelles that inhibit MCT 1 and related proteins [patent_app_type] => utility [patent_app_number] => 17/239742 [patent_app_country] => US [patent_app_date] => 2021-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 14272 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 138 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17239742 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17168775 [patent_doc_number] => 20210322445 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => PHARMACEUTICAL COMPOSITIONS OF NICLOSAMIDE [patent_app_type] => utility [patent_app_number] => 17/220833 [patent_app_country] => US [patent_app_date] => 2021-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21940 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17220833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17124330 [patent_doc_number] => 20210299098 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => SELECTIVE ESTROGEN RECEPTOR MODULATOR FOR TREATMENT OF PANCREATIC CANCER [patent_app_type] => utility [patent_app_number] => 17/216756 [patent_app_country] => US [patent_app_date] => 2021-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4947 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17216756 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17895284 [patent_doc_number] => 20220304946 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => TRANS-ANETHOLE ((E)-1-METHOXY-4- (1-PROPENYL) BENZENE), A NEW AND POTENT INHIBITOR OF PROLYL ENDOPEPTIDASE [patent_app_type] => utility [patent_app_number] => 17/214886 [patent_app_country] => US [patent_app_date] => 2021-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1576 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17214886 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18296837 [patent_doc_number] => 20230106523 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-06 [patent_title] => QUERCETIN ENHANCEMENT FORMULATION [patent_app_type] => utility [patent_app_number] => 17/907239 [patent_app_country] => US [patent_app_date] => 2021-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9697 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17907239 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17154829 [patent_doc_number] => 20210315880 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => METHODS OF TREATING VIRAL INFECTIONS USING INHIBITORS OF NUCLEOTIDE SYNTHESIS PATHWAYS [patent_app_type] => utility [patent_app_number] => 17/207504 [patent_app_country] => US [patent_app_date] => 2021-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47121 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17207504 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17065722 [patent_doc_number] => 20210267937 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => METHODS FOR THE TREATMENT OF INFLAMMATION [patent_app_type] => utility [patent_app_number] => 17/189482 [patent_app_country] => US [patent_app_date] => 2021-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10024 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17189482 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17814249 [patent_doc_number] => 11419836 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-23 [patent_title] => Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions [patent_app_type] => utility [patent_app_number] => 17/190062 [patent_app_country] => US [patent_app_date] => 2021-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 4 [patent_no_of_words] => 11607 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 262 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17190062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17110041 [patent_doc_number] => 20210290638 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-23 [patent_title] => COMPOSITION AND METHOD FOR PROMOTING PROSTATE HEALTH [patent_app_type] => utility [patent_app_number] => 17/186600 [patent_app_country] => US [patent_app_date] => 2021-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4021 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17186600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17355321 [patent_doc_number] => 20220016117 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => THIENOPYRIMIDINONE NMDA RECEPTOR MODULATORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/186137 [patent_app_country] => US [patent_app_date] => 2021-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21926 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17186137 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18158947 [patent_doc_number] => 20230025539 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => METHOD FOR REDUCTION OF BEHAVIORAL DISORDERS IN PIGS [patent_app_type] => utility [patent_app_number] => 17/758317 [patent_app_country] => US [patent_app_date] => 2021-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5351 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17758317 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19563484 [patent_doc_number] => 12138233 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-12 [patent_title] => Methods of treating idiopathic hypersomnia [patent_app_type] => utility [patent_app_number] => 17/180991 [patent_app_country] => US [patent_app_date] => 2021-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 22510 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17180991 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18102389 [patent_doc_number] => 11542264 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-03 [patent_title] => Heteroaromatic NMDA receptor modulators and uses thereof [patent_app_type] => utility [patent_app_number] => 17/174826 [patent_app_country] => US [patent_app_date] => 2021-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 6331 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17174826 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17035014 [patent_doc_number] => 20210251972 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => Methods Of Treating Fabry Disease [patent_app_type] => utility [patent_app_number] => 17/172846 [patent_app_country] => US [patent_app_date] => 2021-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20026 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17172846 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18250944 [patent_doc_number] => 20230077983 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => METHODS OF TREATING AND PREVENTING ENGRAFTMENT ARRHYTHMIAS [patent_app_type] => utility [patent_app_number] => 17/798127 [patent_app_country] => US [patent_app_date] => 2021-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20991 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17798127 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17952372 [patent_doc_number] => 11478444 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-25 [patent_title] => Use of scientifically matched plant supplements combined with antineoplastic compounds for the treatment of hematological malignancies [patent_app_type] => utility [patent_app_number] => 17/168644 [patent_app_country] => US [patent_app_date] => 2021-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 20 [patent_no_of_words] => 21521 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17168644 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20577220 [patent_doc_number] => 12569455 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-10 [patent_title] => Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome [patent_app_type] => utility [patent_app_number] => 17/795609 [patent_app_country] => US [patent_app_date] => 2021-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 0 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17795609 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17124296 [patent_doc_number] => 20210299064 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => METHOD OF TREATING PATIENTS WITH LENNOX-GASTAUT SYNDROME [patent_app_type] => utility [patent_app_number] => 17/164403 [patent_app_country] => US [patent_app_date] => 2021-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13205 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17164403 [rel_patent_id] =>[rel_patent_doc_number] =>)